Journal of Hepatology
Volume 48, Issue 5 , Pages 687-691 , May 2008

Combination therapy for chronic hepatitis B: Ready for prime time?

References 

  1. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  2. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
  3. Niederau C, Heintges T, Lenge S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HbeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  4. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  5. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis in relation to virological response to lamivudine. Hepatology. 2004;40:883–891
  6. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–767
  7. Yang LM, Xu KC, Zhao YL, Wu ZR, Chen TF, Qin ZY, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminases. Chin J Dig Dis. 2002;4:150–153
  8. Yuen MF, Yuan HJ, Wong DKH, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–1614
  9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  10. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;38:S3–S25.
  11. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472–489
  12. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936–962
  13. Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita KD, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 2. Hepatology 2007;46:290A.
  14. Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, Manns MP, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. American Association for the Study of Liver Diseases, 58th annual meeting, 2007: late breaking abstract 6. Hepatology 2007;46:861A.
  15. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off therapy viral suppression. Hepatology. 2007;46:1041–1048
  16. Gish R, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Hepatitis B surface antigen loss in antiviral-treated patients with HBeAg-positive chronic hepatitis B infection: observations from antiviral-naïve patients treated with entecavir or lamivudine. 57th annual meeting of the American Association for the Study of Liver Diseases, 2006. Hepatology 2006;44:558A.
  17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
  18. Han S, Chang TT, Chao YC, Yoon S-K, Gish RG, Cheinquer H, et al. Four-year entecavir treatment in nucleoside-naive HbeAg+ patients: results from studies ETV-022 and -901. Hepatology. 2007;46:654A
  19. Sherman M, Rizzetto M, Lai CL, Liaw Y-F, Gadano A, Jacobson IM, et al. Long-term follow-up of entecavir treated protocol-defined nonresponders in rollover study ETV-901. Hepatology. 2007;46:682A
  20. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007;46:631–639
  21. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  22. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451
  23. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008;48:728–735
  24. Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung K-W, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine versus adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol. 2008;48:714–720
  25. Sung JJY, Lau JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine and adefovir for treatment-naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol. 2003;38:25–26
  26. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49–56
  27. Van Bommel F, De Man RA, Erhardt A, Huppe D, Stein K, Buggish P, et al. First multicenter evaluation of the efficacy of tenofovir in nucleos(t)ide analog experienced patients with HBV monoinfection. Hepatology. 2007;46:270A
  28. Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006;43:548–555
  29. Zeuzem S, Buti M, Gane EJ, Liaw Y-F, Di Bisceglie AM, Heathcote EJ, et al. Baseline parameters predict both early virologic response and longer term outcomes for telbivudine-treated patients with chronic hepatitis B (the GLOBE Study). Hepatology. 2007;46:681A
  30. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  31. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695
  32. http://clinicaltrials.gov/.
  33. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–897

☆ Dr. Ira M. Jacobson declares that he is a consultant, speaker and investigator for Schering Plough; Gilead Sciences, Novartis and Idenix; a consultant and speaker for Bristol Myers Squibb; an investigator for Roche; and a consultant for Nucleonics.

PII: S0168-8278(08)00126-8

doi: 10.1016/j.jhep.2008.02.006

Journal of Hepatology
Volume 48, Issue 5 , Pages 687-691 , May 2008

Article Tools